StockPreacher.com announces investment report featuring Generex Biotechnology

Mar 12 2010

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. (Nasdaq:GNBT). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/GNBT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Generex Biotechnology Corp. (GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its wholly owned subsidiaries include Generex Pharmaceuticals Inc., Antigen Express Inc., Generex (Bermuda) Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. The Company is in development stage. In September 2009, the Company announced the incorporation of SIA Generex Biotechnology BALTIC as a wholly owned subsidiary. 

Message Board Search for GNBT: http://www.boardcentral.com/boards/GNBT

In the report, the analyst notes:

"GNBT net loss for the quarter ended January 31, 2010, was $7,315,462 versus $12,038,440 in the corresponding quarter of the prior fiscal year. The decrease in net loss in this fiscal quarter versus the corresponding quarter of the prior fiscal year is primarily due to the prior year's quarter interest expense of $6,363,197, which consisted mainly of non-cash interest charges recorded in connection with the Company's secured convertible debentures. 

"GNBT recently announced that Health Management Resources Inc. (HMR) conducted two focus groups in Indianapolis for Generex Oral-lyn(TM). HMR provides educational programs, materials and services to the healthcare industry. ... The focus groups were designed to determine the perception and opinions of these healthcare practitioners regarding Generex Oral-lyn. The positive opinions expressed by both groups state that Generex Oral-lyn is a suitable alternative prandial insulin product."